Immune Effects

Aspirin's immune relevance goes well beyond inflammation control.

Its strongest emerging mechanism is relief of platelet-driven T-cell suppression.

This overlaps directly with the TXA2 pathway covered in Aspirin and Thromboxane A2 (TXA2).

Immune overview

Platelets do more than support clotting.

In cancer, they can shield circulating tumour cells and suppress immune attack.

Aspirin weakens that platelet help through irreversible COX-1 inhibition.

The platelet–T-cell pathway

Platelets are a major source of thromboxane A2 (TXA2).

TXA2 suppresses anti-tumour CD8+ T cells through an ARHGEF1-linked pathway inside the T cell.

That matters most during metastasis.

Circulating tumour cells are briefly exposed to immune attack. Platelet-derived TXA2 helps them survive that window.

By blocking platelet COX-1, aspirin lowers TXA2 generation.

That appears to release T cells from part of this suppression and strengthen anti-metastatic immunity.

A 2025 Nature study linked this mechanism directly to reduced metastasis in T-cell-dependent models. The signal was not explained by inflammation control alone.

Effects in colorectal tumour tissue

Colorectal cancer provides some of the most interesting tissue-level immune data.

Regular aspirin use has been associated with higher immune-cell infiltration in tumours and less lymph-node spread.

Tissue studies also suggest aspirin may increase CD80 expression on antigen-presenting cells.

That could improve immune recognition of tumour-associated proteins.

Aspirin has also been linked to lower TIGIT expression on regulatory T cells (Tregs).

That points toward less local immune suppression and more room for effector T-cell activity.

These findings are promising.

They are still best read as translational support, not proof of a universal clinical effect.

The immunotherapy angle

Many tumours produce PGE2 to dampen immune attack.

COX inhibition can reduce that signal.

In preclinical bowel-cancer and melanoma models, aspirin plus immunotherapy slowed tumour growth more than immunotherapy alone.

That makes the combination biologically interesting.

It does not make it standard care.

Discussing Aspirin with an oncologist or immunologist would have to be one of the easier off-label discussions to have however immunotherapy remains a research direction in 2026 and not a routine oncology recommendation outside trials or clinician-led use.

Practical interpretation

The immune case for aspirin is now stronger than a generic anti-inflammatory story.

The most important mechanism is platelet TXA2 reduction and the resulting release of T-cell suppression.

That gives aspirin a credible immune-surveillance and anti-metastatic rationale, especially in colorectal-cancer discussions.

Real-world use has to be weighed against bleeding risk, surgery timing, platelet count, and anticoagulant use.

Key References

• Platelet–T-cell mechanism: Yang et al. — Nature 2025: Aspirin prevents metastasis by limiting platelet TXA2 suppression of T-cell immunity and PubMed record

• Colorectal immune infiltration: IMMUNOREACT 7 — regular aspirin use and immune infiltration in colorectal cancer and Wiley summary of the colorectal tissue findings

• Immunotherapy combination rationale: Ecancer summary — aspirin and cancer immunotherapy

Would you like to ask Abbey about the information shared on this page? Would you like to contribute your experience, research or ideas to this page? Perhaps you want to point out something that needs changing?

Feedback Form